BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: Accordingly, TKI-sensitive CML cell lines genetically engineered to contain the deletion expressed less pro-apoptotic BH3-containing BIM isoforms upon exposure to imatinib, resulting in an impaired apoptotic response to TKIs, and a relative TKI resistance [1].